Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection.
OBJECTIVE
To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal phase, on intracytoplasmic sperm injection (ICSI) outcome.


METHODS
One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study. Patients were randomly assigned to receive a single dose of GnRH agonist or placebo. Implantation rate and clinical pregnancy rate were the main outcomes.


RESULTS
Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo.


CONCLUSIONS
Luteal phase GnRH agonist administration enhances ICSI clinical outcomes.
Razieh
Dehghani Firouzabadi
DF
Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Maryam
Ayazi Rozbahani
AR
Nasim
Tabibnejad
T
D000328:Adult; D010064:Embryo Implantation / Q000187:drug effects*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008183:Luteal Phase / Q000502:physiology*; D008186:Luteolytic Agents / Q000494:pharmacology*; D010062:Ovulation Induction / Q000379:methods; D010919:Placebos; D011247:Pregnancy; D018873:Pregnancy Rate; D020554:Sperm Injections, Intracytoplasmic / Q000379:methods*; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000494:pharmacology*
D008186:Luteolytic Agents; D010919:Placebos; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone